Citations

Clear

118 citation(s) found for "Awad, K".

Serum neurofilament light chain in diabetic patients with and without polyneuropathy: a systematic review and meta-analysis
Metwally, Sara Ahmed, Ali, Shahd Al Haj, Badawy, Mohamed A. , AlAref, Muhammad Moataz, Mousa, Hisham, Ramadan, Ahmed Gaber , Tarek, Ziad, Aboelatta, Mohamed, Al-Twisi, Laial , Elkholy, Mohammed Elsayed, Awad, Ezzat M, Metwally, Sara Ahmed , Mohamed, Khaled Ashraf , Badawy, Mohamed Ahmed, Bedewi, Mohamed Abdelmohsen , Awad, Ezzat Mohamed

Mayo Clinic

No container title available | January 27, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-8394292/v1 Get It

Abstract Background Diabetes mellitus is a prevalent global health issue, affecting approximately 14% of individuals as latest reported. Among its complications, diabetic peripheral polyneuropathy (DPN) is a major cause of morbidity, impacting up to half of patients with long-standing diabetes. Given the limitations of current diagnostic methods, there is an urgent need for reliable biomarkers for early detection and management of DPN. Neurofilament light chain (NFL), a structural neuronal protein, has been proposed as a potential biomarker due to its release into the blood and cerebrospinal fluid following axonal damage. This systematic review and meta-analysis aim to evaluate serum NFL levels in diabetic patients with and without polyneuropathy compared to healthy controls. Methods A systematic search was conducted in four databases: Web of Science, PubMed, Scopus, and Embase. Studies were included if they measured serum NFL levels in diabetic patients, with or without polyneuropathy, and compared these levels to healthy controls. The Newcastle-Ottawa Scale (NOS) and JBI Critical Appraisal tools were used for quality assessment. We performed a meta-analysis using Review Manager 5.4 version, and assessed heterogeneity through chi-square tests and I² statistics. Results Eight studies (n = 2980 participants, including 950 diabetic patients and 2030 healthy controls) met the inclusion criteria. Three studies specifically evaluated serum NFL levels in diabetic patients with polyneuropathy. Meta-analysis revealed significantly elevated serum NFL levels in diabetic patients compared to healthy controls. Similarly, diabetic patients with polyneuropathy exhibited higher NFL levels than healthy controls. However, due to the limited number of studies comparing diabetic patients with and without neuropathy, a definitive conclusion on NFL's specificity to DPN remains uncertain. Heterogeneity analysis showed a moderate to high variation among studies, with a slight reduction after sensitivity analysis. Conclusion This study highlights elevated serum NFL levels in diabetic patients, irrespective of polyneuropathy status, suggesting that diabetes itself may contribute to increased NFL release. However, due to limited studies assessing NFL in DPN, further research is required to clarify its role as a specific biomarker for DPN.
Z-coded social determinants of health and cardiovascular risk among patients receiving dialysis
Alhammouri, Hashim, Ibrahim, Ramzi , AlAsmar, Rahmeh, Dreher, Luke, Almakadma, Abdul Hakim , Pham, Hoang Nhat, Mahmoud, Ahmed K, Awad, K, Abdelnabi, Mahmoud, Salih, Mohammed, Agarwal, Siddharth, Al‐Kindi, Sadeer , Sorajja, Dan , Scott, Luis R, Ayoub, C A, Arsanjani, R A, Awad, Kamal , Al-Kindi, Sadeer , Sorajja, Dan , Ayoub, Chadi , Ibrahim, Ramzi , Al-Asmar, Rahmeh , Dreher, Luke , Pham, Hoang Nhat , Awad, Kamal , Abdelnabi, Mahmoud , Agarwal, Siddharth , Hommos, Musab S. , Arsanjani, Reza

Mayo Clinic

Journal of Nephrology | January 6, 2026 | Volume: 39 | Issue: 3 | Pages: 528-535

10.1093/joneph/aajaf060 | PMID 42189835 Get It

Abstract Introduction Cardiovascular disease (CVD) is the leading cause of death among patients with kidney failure on dialysis. Social determinants of health may worsen this risk but are seldom incorporated into prognostic models. ICD-10 Z-codes provide standardized documentation of social determinants of health, yet their prognostic value in dialysis populations remains uncertain. This study examined whether Z-coded social determinants of health are associated with adverse cardiovascular outcomes and mortality among patients receiving dialysis for kidney failure. Methods A retrospective cohort study was conducted using the TriNetX Research Network (2010–2024), encompassing de-identified data from 103 institutions. Adults with kidney failure on chronic dialysis were stratified by the presence of ICD-10 Z-codes (Z55–Z65). Propensity score matching (1:1) balanced demographics, comorbidities, medications, and laboratory values. Primary outcomes were all-cause mortality and hospitalization; secondary outcomes included acute heart failure, myocardial infarction, stroke, cardiac arrest, bradyarrhythmias, and ventricular tachycardia. Results After matching, mean age was 62 years, and 42.4% were female in the Z-code cohort versus 41.2% in controls. Over one year, mortality occurred in 12.5% versus 10.9% (hazard ratio [HR], 1.22; 95% confidence interval [CI], 1.15–1.29) and all-cause hospitalizations in 57.3% versus 53.1% (HR, 1.22; 95% CI, 1.19–1.26). Cardiovascular complications were consistently higher in Z-coded patients, including heart failure (24.3% vs 20.5%; HR, 1.29), myocardial infarction (8.0% vs 7.1%; HR, 1.19), stroke (6.6% vs 6.2%; HR, 1.13), cardiac arrest (3.8% vs 3.1%; HR, 1.29), and bradyarrhythmias (6.9% vs 5.5%; HR, 1.33). Discussion Among patients with kidney failure, documented Z-coded social risk factors were associated with greater mortality and cardiovascular morbidity. Incorporating social determinants of health documentation into nephrology care may improve risk stratification and inform targeted interventions.
Efficacy of Short- vs Long-Course Antibiotics in Treatment of Hinchey Stage 3 and 4 Diverticulitis
Awad, Amir, Linnaus, Maria E., Theerman, Isaac, Yang, Theodore, York, Justin, Stephens, D. H., Jorge, Irving , Junker, Michelle S., Lara, Francisco J. Cardenas , Rich, Jennifer R. , Kooda, Kirstin , Awad, Abanoub A , Theerman, Isaac L, Jorge, Irving A , Cardenas Lara, Francisco J, Kooda, Kirstin J, Beckermann, Jason

Mayo Clinic

The American Surgeon™ | January 2, 2026 | Volume: 92 | Issue: 6 | Pages: 1701-1706

10.1177/00031348251409742 | PMID 41481278 Get It

Background This study aimed to evaluate outcomes of different antibiotic durations in patients with severe diverticulitis. Methods Initial electronic medical record review identified 2437 adult patients who underwent sigmoid colectomy. Manual chart review identified 133 patients who underwent sigmoid resection and proximal diversion for Hinchey stage 3 or 4 diverticulitis. Patients who received a short antibiotic course (SAC, ≤5 days) were compared with those who received a long antibiotic course (LAC, >5 days). The primary composite outcome included superficial, incisional, organ-space infections or death within 30 days post procedure. Results A total of 53 SAC patients and 55 LAC patients were identified. The composite outcome occurred more frequently in LAC patients than in SAC patients (40% vs 15%; P = .005). Organ-space infection occurred more frequently in LAC patients than in SAC patients (31% vs 13%; P = .04). Conclusions Extended duration of antibiotics after adequate source control does not improve outcomes even in the setting of extensive intra-abdominal contamination.
Risk of rhabdomyolysis with concomitant use of statins and SGLT2 inhibitors: A population‐based cohort study
Awad, Kamal, Mahmoud, Ahmed K., Sheashaa, Hesham, Scalia, Isabel G. , Abdelfattah, Fatmaelzahraa , Razaghi, Mahshad , Mousa, Hana, Lester, Steven J., Arsanjani, Reza, Awad, Kamal , Sheashaa, Hesham , Pietri, Milagros Pereyra, Scalia, Isabel G , Ayoub, Chadi , Awad, Kamal , Mahmoud, Ahmed , Abbas, Mohammed Tiseer , Pereyra, Milagros , Ibrahim, Ramzi , Farina, Juan M. , Arsanjani, Reza

Mayo Clinic

Journal of Internal Medicine | December 22, 2025 | Volume: 299 | Issue: 3 | Pages: 417-419

10.1111/joim.70062 | PMID 41424321 Get It

Evaluation of ePLAR, the echocardiographic pulmonary to left atrial ratio, in a large cohort with pulmonary hypertension
Scalia, Isabel G. , Ali, Nima Baba , Bismee, Nadera N. , Mahmoud, Ahmed K, Esfahani, Sogol Attaripour , Sheashaa, Hesham, Ibrahim, Oman H, Abdelfattah, Fatmaelzahraa , Barry, Timothy, Tamarappoo, Balaji , Scott, Robert L, Rosenthal, Julie , Lester, Steven J, Ayoub, Chadi, Arsanjani, Reza, Mahmoud, Ahmed , Scalia, Isabel G , Pietri, Milagros Pereyra, Awad, Kamal , Javadi, Niloofar , Mahmoud, Ahmed K , Tamarappoo, Balaji K, Alsidawi, Said , Ayoub, Chadi , Farina, Juan M. , Pereyra, Milagros , Abbas, Mohammed Tiseer , Awad, Kamal , Barry, Timothy , Alsidawi, Said , Scott, Robert L. , Lester, Steven J., Arsanjani, Reza

Mayo Clinic

European Heart Journal Open | December 18, 2025 | Volume: 6 | Issue: 3 | Pages: No page available

10.1093/ehjopen/oeaf174 | PMID 42282056 Get It

Abstract Aims Pre-capillary pulmonary hypertension (PHTN), typically due to intrinsic pulmonary pathology, requires right heart catheterization (RHC) for diagnosis. ePLAR, the echocardiographic pulmonary to left atrial ratio [calculated: tricuspid regurgitation maximum velocity (TRVmax) divided by mitral valve E to e′ wave ratio (E/e′)], has been demonstrated as a promising non-invasive surrogate for characterization of pre-capillary PHTN. As such, this study aimed to further evaluate the diagnostic utility of ePLAR in a large cohort of patients with PHTN. Methods and results All RHCs between 2018 and 2023 across three tertiary centres were retrospectively reviewed. Patients with PHTN were characterized as pre-capillary or post-capillary (isolated or combined). Concurrent ePLAR was calculated. ROC analysis evaluated the accuracy of ePLAR in detecting pre-capillary PHTN. Overall, 2235 patients had PHTN by RHC, mean age 63.5 ± 14.7 years, 53.5% male. Of these, 43.3% had pre-capillary PHTN. ROC analysis demonstrated ePLAR to have good accuracy in detection of pre-capillary PHTN (AUC 0.760), with a cutoff of 0.20 m/s demonstrating a sensitivity and specificity of 77% and 60% respectively. This persisted on sensitivity analysis for contemporaneous investigations and for right ventricular function. Conclusion In this large cohort, ePLAR was validated as an accurate tool for identifying patients with pre-capillary PHTN. This widely available, non-invasive, and reproducible parameter can have an important role in the work up of PHTN and may guide the need for invasive testing.
Early and Sustained Shift in Headache Day Frequency Following Eptinezumab Treatment in Adults With Migraine for Whom 2–4 Previous Preventive Treatments Have Failed: A Post Hoc Analysis of the Randomized DELIVER
Tassorelli, Cristina , Starling, Amaal J. , Awad, Susanne F. , Pickering, Line , Asher, Divya , Soni-Brahmbhatt, Seema , Sperling, Bjørn, Goadsby, Peter J. , Lee, Xin Ying , Boserup, Line Pickering , Asher, Divya , Soni-Brahmbhatt, Seema , Goadsby, Peter J , Starling, Amaal J , Lee, Xin Ying

Mayo Clinic

European Journal of Neurology | December 15, 2025 | Volume: 32 | Issue: 12 | Pages: No page available

10.1111/ene.70460 | PMID 41395928 Get It

ABSTRACT Background This post hoc analysis examined the reduction in monthly headache days ( MHDs ) by frequency category shifts and associated improvements following eptinezumab treatment. Methods The DELIVER trial evaluated eptinezumab in adults with migraine for whom 2–4 previous preventive treatments failed. During a 24‐week, double‐blind, placebo‐controlled period followed by a 48‐week extension period, participants received IV eptinezumab 100 mg, 300 mg, or placebo every 12 weeks, with all receiving eptinezumab beginning Week 25 (dose‐blinded). Participants were categorized by MHD frequency: > 14, 8–14, 4 to < 8, 1 to < 4, 0. MHD category shifts were evaluated in the total population and several subgroups (including participants with > 14 baseline MHDs and early ≥ 50% responders). In participants reporting < 8 MHDs after all doses, the associated changes in headache intensity and disease status were evaluated. Results Of randomized participants, 88% (782/890) completed the trial. The percentage of participants randomized initially to eptinezumab who reported < 4 MHDs was 23% (138/592) over Weeks 1–12 and 47% (236/498) over Weeks 61–72; 9% reported 0 MHDs after the final dose. Of participants randomized initially to eptinezumab who shifted from ≥ 8 MHDs at baseline to < 8 over Weeks 1–12, 71% (170/241) reported < 8 MHDs for the rest of the trial; of those who shifted from > 14 to < 8 MHDs, 66% (49/74) reported < 8 MHDs for the rest of the trial. Reduction to < 8 MHDs was associated with robust improvements in headache intensity and disease burden. Conclusions Eptinezumab was associated with sustained reduction in MHD category, with some achieving headache/migraine freedom in patients with a history of preventive treatments that failed. Trial Registration ClinicalTrials.gov (identifier: NCT04418765; https://www.clinicaltrials.gov/ct2/show/NCT04418765 ) and EudraCT (identifier: 2019‐004497‐25; https://www.clinicaltrialsregister.eu/ctr‐search/search?query=2019‐004497‐25 )
Diagnostic and Prognostic Value of High‐Sensitivity Troponin T for Cardiovascular Outcomes in Patients Receiving Immune Checkpoint Inhibitor Therapy
Pereyra, Milagros , Kanaan, Christopher , Tagle‐Cornell, Cecilia, Novais, Barbara S., Koepke, Laura, Kenyon, Courtney , Mahmoud, Ahmed , Ali, Nima Baba , Narayanasamy, Hemalatha , Tamarappoo, Balaji , Herrmann, Joerg, Ayoub, Chadi , Pereyra, Milagros , Kanaan, Christopher N , Tagle-Cornell, Cecilia, Koepke, Laura M, Kenyon, Courtney R , Mahmoud, Ahmed K , Abbas, Mohammed Tiseer , Baba Ali, Nima , Larsen, Carolyn M , Narayanasamy, Hema , Lee, Kwan S , Arsanjani, Reza , Ayoub, Chadi , Farina, Juan M. , Awad, Kamal , Scalia, Isabel G. , Abbas, Mohammed Tiseer , Larsen, Carolyn , Lee, Kwan , Herrmann, Joerg, Arsanjani, Reza

Mayo Clinic

Journal of the American Heart Association | November 26, 2025 | Volume: 15 | Issue: 6 | Pages: No page available

10.1161/jaha.125.041680 | PMID 41294120 Get It

Background Immune‐checkpoint inhibitors (ICI) are associated with adverse cardiac events. Although troponin elevation is a diagnostic criterion for ICI‐related myocarditis (ICIrM) and myocardial infarction, data on other causes of troponin elevation and their outcomes in ICI‐treated patients are limited. Methods All patients treated with ICI who had hs‐TnT (high‐sensitivity troponin T) measured at a multicenter institution from 2011 to 2022 were included. Clinical data, outcomes (cardiac death, heart failure (HF), major adverse cardiovascular events [myocardial infarction, stroke, heart failure]), and cause of hs‐TnT elevation were assessed. Risks of cardiac events were compared across hs‐TnT elevation causes. Results Of 5423 patients treated with ICI, 1669 had post‐ICI hs‐TnT measurement (mean age 68.7±11.3 years, 58.3% male), with 1‐year follow‐up. Hs‐TnT elevation in patients with ICIrM (n=59) was associated with the highest risk for cardiac death (hazard ratio [HR], 52.7 [95% CI, 11.7–238.0], P <0.001), followed by hs‐TnT elevation due to heart failure (HR, 15.9), myocardial infarction/type 2 ischemia (HR, 11.6), and infection/sepsis (HR, 5.7), compared with those with no hs‐TnT elevation. ICIrM also carried highest risk for major adverse cardiovascular events (HR, 8.2, [95% CI, 4.4–15.3], P <0.001), followed by myocardial infarction/type 2 ischemia (HR, 8.1), heart failure (HR, 7.6), pulmonary embolus (HR, 5.1), infection/sepsis (HR, 4.1), and indeterminate cause (HR, 2.4). Among ICIrM, HsTnT value >576 ng/L best predicted risk for cardiac death and >319 ng/L for major adverse cardiovascular events. Conclusions Hs‐TnT elevation after ICI therapy is associated with increased risk of cardiac events, particularly in ICIrM, and a graded prognostic association depending on the cause of hs‐TnT elevation. Identifying the underlying cause and troponin thresholds may guide risk stratification and management.
Patient-reported benefits of colonoscopicallyadministered microbiota restoration therapy: a qualitative study of adult patients with recurrent Clostridioides difficile infection
Umanzor, Cindy , Symonds, Tara , Landeira, Margarita, Armandi, Daniel, Guthmueller, Beth, Khanna, Sahil , Umanzor-Figueroa, Cindy , Khanna, S , McCool-Myers, Megan , Awad, Tahany

Mayo Clinic

Therapeutic Advances in Gastroenterology | November 14, 2025 | Volume: 18 | Issue: No issue available | Pages: No page available

10.1177/17562848251392102 | PMID 41647268 Get It

Background: Recurrent Clostridioides difficile infection (rCDI) disrupts health-related quality of life (HRQoL), often causing debilitating symptoms, emotional distress, and social withdrawal. Fecal microbiota, live-jslm (RBL; REBYOTA ® ) is approved by the FDA to reduce CDI recurrence. While the burden of rCDI is well established, less is known about the patient experience after RBL treatment and its impact on HRQoL. Objectives: To explore the burden of rCDI on HRQoL, and any improvements in symptoms and impacts after RBL administration by colonoscopy. Design: A qualitative sub-study embedded in the CDI-SCOPE phase IIIb clinical trial (NCT05831189). Methods: Qualitative interviews were conducted with 30 trial participants approximately 8 weeks after RBL treatment. Interviews were conducted using a semi-structured discussion guide; they were audio-recorded, transcribed verbatim, and thematically analyzed. Results: Thirty of 41 trial participants (73%) took part in the qualitative interviews (July 2023–September 2024). Participants (mean age 59 years; 87% female) had experienced multiple prior rCDI episodes. Before RBL treatment, participants reported severe symptoms, including diarrhea (30/30; 100%), abdominal pain (21/30; 70%), and fatigue (14/30; 47%), which negatively affected daily life, social interactions, and emotional health. Eight weeks after RBL treatment, no participants reported a recurrence. Diarrhea symptoms resolved (17/30; 57%) or improved (13/30; 43%) for all participants, typically within 1 month. Average severity scores for diarrhea declined markedly (from 8.9 to 1.3). Every participant (100%) reported improved ability to engage in daily activities; nearly all (29/30; 97%) described positive changes to social life/relationships, and 77% (23/30) reported improved emotional well-being. Conclusion: RBL administered via colonoscopy provided rapid, meaningful relief from rCDI symptoms, and due to symptom improvements, many participants reported that they were able to resume daily life. These findings highlight the broader value of RBL in restoring HRQoL and overall well-being. Trial registration: ClinicalTrials.gov: NCT05831189.
Lipoprotein(a) and mortality in primary prevention: only very high levels matter
Arsanjani, Reza, Awad, Kamal , Awad, Kamal , Farina, Juan M. , Arsanjani, Reza

Mayo Clinic

European Journal of Preventive Cardiology | November 13, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/eurjpc/zwaf707 | PMID 41230763 Get It

Prevention of recurrent Clostridioides difficile infection by fecal microbiota, live-jslm (REBYOTA ® ) administered via colonoscopy: 6-month data from the sin
Khanna, Sahil , Yoho, David, Handel, Daniel Van, Clark, Brian J., Guthmueller, Beth, Armandi, Daniel, Knapple, W , Safdar, Nasia , Baggott, Brian, Simon, Karen, Knapple, Whitfield , Feuerstadt, Paul , Awad, Tahany , Feuerstadt, Paul

Mayo Clinic

Therapeutic Advances in Gastroenterology | November 10, 2025 | Volume: 18 | Issue: No issue available | Pages: No page available

10.1177/17562848251396744 | PMID 41230019 Get It

Background: Fecal microbiota, live-jslm (RBL) is a microbiota-based product for the prevention of recurrent Clostridioides difficile infection (rCDI) in adults following antibiotic treatment. The safety and clinical effectiveness of RBL administered via colonoscopy in adults with rCDI were evaluated in CDI-SCOPE. An 8-week analysis showed 9.8% of participants had RBL-related treatment-emergent adverse events (TEAEs; primary endpoint) and 95.1% experienced treatment success (no CDI recurrence). Objectives: To evaluate long-term safety and clinical effectiveness of RBL through 6 months of follow-up in CDI-SCOPE. Design: Single-arm exploratory phase IIIb trial conducted at 12 sites in the United States. Methods: Eligible adults with rCDI received a single 150-mL dose of RBL to the right colon via colonoscopy. The primary endpoint was RBL-related TEAEs through 8 weeks after RBL administration or confirmed treatment failure. Secondary endpoints included safety up to 6 months after RBL administration. Exploratory analyses included assessment of further CDI episodes. Results: Of the 41 participants enrolled, 39 completed trial assessments through 6 months. From 8 weeks through 6 months after RBL administration, 36 TEAEs in 15 participants (36.6%) were reported, one of which (irritable bowel syndrome) was RBL-related; most TEAEs (97.2%) were of mild or moderate severity. Over the 6-month trial period, 23 participants (56.1%) experienced 69 TEAEs; 94.2% were of mild or moderate severity. Serious TEAEs occurred in three participants (7.3%), none of which were related to RBL or its administration, and no TEAEs led to discontinuation or death. Overall, 38 participants (92.7%) did not experience further CDI episodes, 1 (2.4%) did between 8 weeks and 6 months, and 2 (4.9%) had an indeterminate outcome due to trial withdrawal before 8 weeks. Conclusion: RBL administered via colonoscopy was safe and effective for preventing CDI recurrence in adults with rCDI in CDI-SCOPE. Trial registration: ClinicalTrials.gov: NCT05831189.